ANAI peoples were included in clinical trials of the COVID-19 vaccine developed by Pfizer. But not at the same level as other races and ethnicities. In general, about 0.6% of Pfizer clinical trial participants were ANAI peoples, or around half the rate of overall population of ANAI people in the United States, which is 1.3%.